Related content

Luteal phase treatment with mifepristone and misoprostol for fertility regulation

By Xiao B.   von Hertzen H.   Zhao H.   Piaggio G.  

Contraception, Vol. 68, Iss. 6, 2003-12 ,pp. : 477-482

Elsevier

Access to resources Recommend Favorite

Mifepristone medical abortion in Albania: Results from a pilot clinical research study

By Group The Medical Abortion Research   Bracken Hillary   Gliozheni Orion   Kati Kreston   Manoku Nikita   Moisiu Rubena   Shannon Caitlin   Tare Vjollca   Tasha Ilir   Winikoff Beverly  

The European Journal of Contraception and Reproductive Health Care, Vol. 11, Iss. 1, 2006-03 ,pp. : 38-46

Informa Healthcare

Access to resources Recommend Favorite

Acceptability and feasibility of the use of 400 μg of sublingual misoprostol after mifepristone for medical abortion up to 63 days since the last menstrual period: Evidence from Uzbekistan

By Raghavan Sheila  

The European Journal of Contraception and Reproductive Health Care, Vol. 18, Iss. 2, 2013-04 ,pp. : 104-111

Informa Healthcare

Access to resources Recommend Favorite

Mifepristone: bioavailability, pharmacokinetics and use-effectiveness

By Sarkar N.N.  

European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol. 101, Iss. 2, 2002-03 ,pp. : 113-120

Elsevier

Access to resources Recommend Favorite

Fibroids and fertility: a review of the evidence

By Knox Andrew   McClure Neil  

Expert Review of Obstretrics and Gynecology, Vol. 7, Iss. 1, 2012-01 ,pp. : 31-39

Informa Healthcare

Access to resources Recommend Favorite